Interaction of interleukin-6 and angiotensin II in atherosclerosis: Culprit for inflammation?

European Heart Journal, Supplement

Volumn 5, Issue A, 2003, Pages

  Schieffer, Bernhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Angiotensin II; Atherosclerosis; C reactive protein; Interleukin 6; Matrix metalloproteinases; Renin angiotensin system (RAS)

Indexed keywords

ANGIOTENSIN; C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL INTERACTION; CONFERENCE PAPER; DISEASE COURSE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0037246521     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90060-5     Document Type: Conference Paper

References (52)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342(3): 145-53.
2. Ross R. Pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993 362: 801-9.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999 340(2): 115-26.
4. Van der Waal AC, Becker AE, Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994 89: 34-4.
5. Libby P. Molecular bases of the acute coronary syndrome. Circulation 1995; 21: 2844-50.
6. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
7. Aldermann MH, Madhavan S, Ooi WL, Cohen H, Sealy JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-104.
8. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
9. Cambien F, Costerousse O, Tirret L, et al. Plasma levels and gene polymorphism of angiotensin converting enzyme in relation to myocardial infarction. Circulation 1994; 90: 669-76.
10. Rigart B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
11. Alexander R.W. Inflammation and Coronary Artery Disease. N Engl J Med 1994; 331(7): 468-9.
12. Hernandez-Presa M, Bustos C, Ortega M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95: 1532-41.
13. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101: 1586-9.
14. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001 23; 103: 448-54.
15. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997; 96: 3264-5.
16. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8
17. Han Y, Runge M, Brasier A. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-κB transcription factor. Circ Res 1999; 84: 695-703.
18. Schieffer B, Kowert A, Brauer N, et al. Irbesartan inhibits angiotensin II-induced pro-inflammatory and prothrombotic factors in human coronary arteries: role of the JAK/STAT cascade. Eur Heart J 1998; (Suppl.II): 322.
19. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci 1997; 94: 14483-8.
20. Northermann W, Braciak TA, Hattori M, Lee F, Fey GH. Structure of the rat [L-6 gene and its expression in macrophage-derived cells. J Biol Chem 1989; 264: 16072-82.
21. Kishimoto T, Akira S, Narazaki M, Taga T. IL-6 family of cytokines and gp130. Blood 1995; 86: 1243-54.
22. Chakraborti S, Chakraborti T. Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: a brief overview. Cell Signal 1998; 10(10): 675-83
23. Eikelboom JW, Hirsh J, Weitz JI et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
24. Fuhrman B, Oiknine J, Aviram M. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL and affect their secretory properties. Atherosclerosis 1994; 111: 65-78.
25. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E deficient mice. Biochem Biophys Res Commun 1997; 236: 622-5.
26. Chobanian AV, Haudenschild CC, Nickerson C, Drago R, Antiartherogenic effect of captopril in Watanabe heritable hyperlipidemic rabbits. Hypertension 1990; 15: 327-31.
27. Hayek T, Keidar S, Mei-Yi, Oikine J, Breslow J. Effect of angiotensin converting enzyme inhibitors on LDL lipid peroxidation and atherosclerosis progression in apoE-deficient mice. Circulation 1995; 92(Suppl 1): 1-625.
28. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15: S65-S72.
29. Ridker PM, Gaboury CJL, Conlin PR, Seely EW, Williams GH, Vaughan DE Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-73.
30. Ridker PM, Vaughan DE. Hemostatic factors and the risk of myocardial infarction. N Engl J Med 1995; 333: 389-90.
31. Pfeffer M, Braunwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77.
32. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 568-74.
33. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40-ligand signaling in atherosclerosis. Proc Natl Acad Sci 1997; 94(5): 1931-6.
34. Fiotti N, Giansante C, Ponte E, et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 1999; 145(1): 51-60.
35. Rabbani R, Topol EJ. Strategies to achieve coronary artery plaque stabilization. Cardiovasc Res 1999; 41: 401-17.
36. Kalra D, Sivusabvasubramanian N, Mann DL. Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation 2002; 105: 2198-205.
37. Biassuci L, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874-7.
38. Marx N, Neumann FJ, Ott I, et al. Induction of cytokine expression in leucocytes in acute myocardial infarction. J Am Coll Cardiol 1997; 30: 165-70.
39. Solis-Herruzo JA, Rippe A, Schrum LW, et al. Interleukin 6 increases ra metalloproteinases-13 gene expression through stimulation of activator protein 1 transcription factor in cultured fibroblasts J Biol Chem 1996; 274: 30919-26.
40. Rekhter MD, Hicks GW, Brammer DW, et al. Hypercholesterolemia causes mechanical weakening of rabbit atheroma: local collagen loss as a prerequisite of plaque rupture. Circ Res 2000; 86: 101-8.
41. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941-4.
42. Davies MJ, Woolf N, Rowles P, Richardson PD. Lipid and cellular constituents of unstable human aortic plaques. Basic Res Cardiol 1994; 89: 33-9.
43. Galis ZS. Metalloproteases in remodeling of vascular extracellular matrix. Fibrin Proteol 1999; 13: 54-63.
44. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503.
45. Van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
46. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-9.
47. Diet F, Pratt R, Berry GJ, Momose N, Gibbons G, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2576-767.
48. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998; 98: 800-7.
49. Ohishi M, Ueda M, Rakugi H, et al. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesion. J Hypertens 1999; 17: 547-53.
50. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-8.
51. Hoshida S, Kato J, Nishino M, et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation 2001 6; 103: 630-3.
52. Schieffer B, Luchtefeld M, Hilfiker A, Drexler H. Activation of the JAK/STAT cascade by angiotensin II depends on the NAD(P)H oxidase. Circ Res 2000; 87: 1195-201.